Related Experiment Video
Updated: Jan 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis
Yukai Chen1, Le Xu1, Shishi Zou2
1Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
The use of immune checkpoint inhibitors (ICIs) - including ipilimumab, nivolumab, and atezolizumab has demonstrated remarkable clinical efficacy in cancer therapy. However, due to the activation of the immune system, ICIs can also precipitate immune-related adverse events (irAEs) across multiple organ systems. Among these toxicities, checkpoint inhibitor-related pneumonitis (CIP) is uncommon but carries substantial mortality and poses notable diagnostic and therapeutic challenges. In this review, we summarize the current advances regarding the risk factors and mechanisms of CIP and provide an overview of its incidence and mortality, imaging characteristics, diagnostic approaches, and treatment strategies.
The use of immune checkpoint inhibitors (ICIs) - including ipilimumab, nivolumab, and atezolizumab has demonstrated remarkable clinical efficacy in cancer therapy. However, due to the activation of the immune system, ICIs can also precipitate immune-related adverse events (irAEs) across multiple organ systems. Among these toxicities, checkpoint inhibitor-related pneumonitis (CIP) is uncommon but carries substantial mortality and poses notable diagnostic and therapeutic challenges. In this review, we summarize the current advances regarding the risk factors and mechanisms of CIP and provide an overview of its incidence and mortality, imaging characteristics, diagnostic approaches, and treatment strategies.
More Related Videos
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pneumonia II: Pathophysiology
Tumor Immunotherapy
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

